At the American Heart Association Scientific Sessions 2024 (November 15-18), leading lipid specialists presented latest analyses from the PALISADE, MUIR and SHASTA Open Label Extension, and REDUCE-IT studies together with new insights into the role of apoC in aortic stenosis.
Read the reports:
- Sustained TG reductions with plozasiran in PALISADE and MUIR and SHASTA-2 OLE
- STRENGTH sub-analysis: Asian vs non-Asian patients
- Increasing TG linked to greater MACE risk
- Icosapent ethyl reduces CV risk irrespective of CAD
- Could APOC3 inhibition prevent aortic stenosis?
Reporting by Jenny Bryan
